Shares of Xvivo Perfusion AB, a Swedish MedTech firm, surged as much as 15% on 11th January 2022 following the news of its connection in the world’s foremost ever pig-to-human heart transplant.
Machinery enhanced by Xvivo Perfusion AB assisted surgeons at the University of Maryland Medical Centre to efficaciously transplant an inherently modified pig’s heart into a 57-year-old man last Friday, according to the firm.
Xvivo Perfusion AB’s Chief Executive Dag Andersson told Bloomberg that he never imagined that it would occur so soon. Andersson stated that the technology exceeded everybody’s expectations.
Andersson stated that the radical procedure, dubbed as xenotransplant, depended on Xvivo Perfusion AB’s technology and that a surgical team in Europe was now facilitating a similar project to the one accomplished in the United States of America.
Human-to-human transplants have already been simplified by utilizing the Xvivo Perfusion AB methodology in clinical trials and the product has begotten a ‘Breakthrough Device Designation’ from American regulators. The CEO stated that they could not wait to commercialize that technology.
Xvivo’s shares were the best performing on the Stockholm All-Shares Index on 11th January, allowing its market worth to rise to USD 926 million.
About Xvivo Perfusion AB
Xvivo is a medical technology firm with headquarters in Gothenburg, Sweden, a production house in Lund, Sweden, and an office in Denver, USA. The firm is cemented into medical science and their core business elaborates ex vivo organ preservation. The firm focuses on enhancing augmented solutions for tissue, cell, and organ preservation and perfusion relating to transplantation. The firm boasts over two decades of experience within the transplant industry and are devoted to providing effective and clinically proven products that both enhance the accessibility to acceptable donor organs and enhance survival post-transplantation procedures.
